company background image
IMC

Immuron ASX:IMC Stock Report

Last Price

AU$0.08

Market Cap

AU$18.2m

7D

-1.2%

1Y

-40.7%

Updated

31 Jan, 2023

Data

Company Financials

IMC Stock Overview

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally.

IMC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Immuron Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Immuron
Historical stock prices
Current Share PriceAU$0.08
52 Week HighAU$0.14
52 Week LowAU$0.07
Beta1.33
1 Month Change-6.98%
3 Month Change3.90%
1 Year Change-40.74%
3 Year Change-41.82%
5 Year Change-68.00%
Change since IPO-99.20%

Recent News & Updates

Recent updates

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Jan 20
We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Oct 01
We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Mar 30
We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Have Insiders Been Selling Immuron Limited (ASX:IMC) Shares This Year?

Feb 05
Have Insiders Been Selling Immuron Limited (ASX:IMC) Shares This Year?

Shareholder Returns

IMCAU BiotechsAU Market
7D-1.2%-1.7%0.4%
1Y-40.7%9.9%3.4%

Return vs Industry: IMC underperformed the Australian Biotechs industry which returned 9.9% over the past year.

Return vs Market: IMC underperformed the Australian Market which returned 3.4% over the past year.

Price Volatility

Is IMC's price volatile compared to industry and market?
IMC volatility
IMC Average Weekly Movement12.4%
Biotechs Industry Average Movement9.1%
Market Average Movement8.5%
10% most volatile stocks in AU Market15.7%
10% least volatile stocks in AU Market3.5%

Stable Share Price: IMC is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: IMC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
19945Steve Lydeamorehttps://www.immuron.com.au

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.

Immuron Limited Fundamentals Summary

How do Immuron's earnings and revenue compare to its market cap?
IMC fundamental statistics
Market CapAU$18.22m
Earnings (TTM)-AU$2.85m
Revenue (TTM)AU$765.19k

23.8x

P/S Ratio

-6.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMC income statement (TTM)
RevenueAU$765.19k
Cost of RevenueAU$241.69k
Gross ProfitAU$523.50k
Other ExpensesAU$3.38m
Earnings-AU$2.85m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.013
Gross Margin68.41%
Net Profit Margin-373.01%
Debt/Equity Ratio0%

How did IMC perform over the long term?

See historical performance and comparison